LeMaitre Vascular, Inc. (NASDAQ:LMAT) Sees Large Increase in Short Interest

LeMaitre Vascular, Inc. (NASDAQ:LMATGet Free Report) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,210,000 shares, an increase of 37.5% from the December 15th total of 880,000 shares. Approximately 5.9% of the company’s shares are sold short. Based on an average daily volume of 157,900 shares, the short-interest ratio is presently 7.7 days.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on LMAT. Oppenheimer reiterated an “outperform” rating and issued a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Barrington Research raised their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective on the stock. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $94.57.

Check Out Our Latest Analysis on LeMaitre Vascular

LeMaitre Vascular Stock Up 0.8 %

NASDAQ:LMAT traded up $0.83 during trading hours on Friday, hitting $99.06. 116,296 shares of the stock traded hands, compared to its average volume of 211,181. LeMaitre Vascular has a 1 year low of $56.04 and a 1 year high of $109.58. The stock has a 50 day moving average price of $98.48 and a 200 day moving average price of $91.80. The company has a market cap of $2.23 billion, a price-to-earnings ratio of 54.13, a price-to-earnings-growth ratio of 2.07 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMATGet Free Report) last released its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $54.82 million for the quarter, compared to the consensus estimate of $53.50 million. During the same quarter in the previous year, the firm earned $0.33 earnings per share. The company’s quarterly revenue was up 15.6% compared to the same quarter last year. Equities analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date was Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 34.97%.

Insider Transactions at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the transaction, the director now directly owns 2,278 shares in the company, valued at $231,148.66. This trade represents a 62.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 10.79% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Driehaus Capital Management LLC boosted its holdings in shares of LeMaitre Vascular by 52.2% in the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock valued at $21,740,000 after buying an additional 90,573 shares in the last quarter. DF Dent & Co. Inc. raised its position in LeMaitre Vascular by 26.2% during the 3rd quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock worth $24,037,000 after buying an additional 53,797 shares during the last quarter. Conestoga Capital Advisors LLC raised its position in LeMaitre Vascular by 1.9% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock worth $183,769,000 after buying an additional 36,850 shares during the last quarter. Rice Hall James & Associates LLC raised its position in LeMaitre Vascular by 15.7% during the 3rd quarter. Rice Hall James & Associates LLC now owns 261,306 shares of the medical instruments supplier’s stock worth $24,273,000 after buying an additional 35,383 shares during the last quarter. Finally, F M Investments LLC raised its position in LeMaitre Vascular by 36.6% during the 3rd quarter. F M Investments LLC now owns 123,545 shares of the medical instruments supplier’s stock worth $11,476,000 after buying an additional 33,087 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

(Get Free Report)

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Featured Articles

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.